Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT 2022

TCT 665: Endocardial radiofrequency septal ablation before TAVI: A novel approach to prevent suicide ventricle

Presenter: Bruno Valdigem

September 19, 2022

Presentation TCT 2022

TCT 681: Alcohol Septal Ablation for Preoperative Optimization Prior to Noncardiac Surgery in Hypertrophic Cardiomyopathy

Presenter: Sina Salehi Omran

September 18, 2022

Presentation TCT 2022

TCT 646: Emergent Alcohol Septal Ablation for Severe Outflow Tract Obstruction while Pregnant and on V-V ECMO for COVID ARDS

Presenter: Michael Hannon

September 18, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

Presentation TVT 2022

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Presenter: David Hsi

June 09, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Advertisement

TCT 665: Endocardial radiofrequency septal ablation before TAVI: A novel approach to prevent suicide ventricle

TCT 681: Alcohol Septal Ablation for Preoperative Optimization Prior to Noncardiac Surgery in Hypertrophic Cardiomyopathy

TCT 646: Emergent Alcohol Septal Ablation for Severe Outflow Tract Obstruction while Pregnant and on V-V ECMO for COVID ARDS

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

What’s Going to Be Hot at ACC 2022, In Person or Virtual

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content